EUR 3.92
(0.0%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 1.56 Million EUR | 101.55% |
2022 | 777.75 Thousand EUR | 341.09% |
2021 | -322.59 Thousand EUR | 53.06% |
2020 | -687.3 Thousand EUR | 33.69% |
2019 | -1.03 Million EUR | -281.31% |
2018 | 571.64 Thousand EUR | -70.4% |
2017 | 1.93 Million EUR | 231.67% |
2016 | 582.23 Thousand EUR | 1416.71% |
2015 | 38.38 Thousand EUR | 44.43% |
2014 | 26.57 Thousand EUR | -89.82% |
2013 | 261.03 Thousand EUR | 174.14% |
2012 | -352.1 Thousand EUR | -170.09% |
2011 | 502.32 Thousand EUR | -10.47% |
2010 | 561.09 Thousand EUR | 380.89% |
2009 | 116.67 Thousand EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 706 Thousand EUR | 0.0% |
2023 FY | 1.56 Million EUR | 101.55% |
2023 Q2 | 1.01 Million EUR | 0.0% |
2023 Q4 | 550.11 Thousand EUR | 0.0% |
2022 FY | 777.75 Thousand EUR | 341.09% |
2022 Q4 | 577 Thousand EUR | 0.0% |
2022 Q2 | 200.75 Thousand EUR | 0.0% |
2021 Q4 | 353.88 Thousand EUR | 0.0% |
2021 FY | -322.59 Thousand EUR | 53.06% |
2021 Q2 | -676.48 Thousand EUR | 0.0% |
2020 Q2 | -958.63 Thousand EUR | 0.0% |
2020 Q4 | 271.33 Thousand EUR | 0.0% |
2020 FY | -687.3 Thousand EUR | 33.69% |
2019 Q2 | -1.04 Million EUR | 0.0% |
2019 Q4 | 9064.00 EUR | 0.0% |
2019 FY | -1.03 Million EUR | -281.31% |
2018 Q2 | 320.51 Thousand EUR | 0.0% |
2018 FY | 571.64 Thousand EUR | -70.4% |
2018 Q4 | 251.13 Thousand EUR | 0.0% |
2017 Q2 | 1.6 Million EUR | 0.0% |
2017 FY | 1.93 Million EUR | 231.67% |
2017 Q4 | 328.98 Thousand EUR | 0.0% |
2016 Q4 | 402.35 Thousand EUR | 0.0% |
2016 Q2 | 179.87 Thousand EUR | 0.0% |
2016 FY | 582.23 Thousand EUR | 1416.71% |
2015 Q2 | 21.91 Thousand EUR | 0.0% |
2015 Q4 | 16.47 Thousand EUR | 0.0% |
2015 FY | 38.38 Thousand EUR | 44.43% |
2014 Q4 | -24.12 Thousand EUR | 0.0% |
2014 FY | 26.57 Thousand EUR | -89.82% |
2014 Q2 | 50.7 Thousand EUR | 0.0% |
2013 Q2 | 106.18 Thousand EUR | 0.0% |
2013 Q4 | 154.85 Thousand EUR | 0.0% |
2013 FY | 261.03 Thousand EUR | 174.14% |
2012 Q3 | -88.02 Thousand EUR | 0.0% |
2012 Q1 | -88.02 Thousand EUR | 0.0% |
2012 Q4 | 65.25 Thousand EUR | 174.14% |
2012 FY | -352.1 Thousand EUR | -170.09% |
2012 Q2 | -88.02 Thousand EUR | 0.0% |
2011 Q3 | 130.29 Thousand EUR | 0.0% |
2011 FY | 502.32 Thousand EUR | -10.47% |
2011 Q4 | -88.02 Thousand EUR | -167.56% |
2011 Q2 | 130.29 Thousand EUR | 0.0% |
2011 Q1 | 130.29 Thousand EUR | 0.0% |
2010 Q1 | 140.27 Thousand EUR | 0.0% |
2010 Q4 | 130.29 Thousand EUR | -7.12% |
2010 FY | 561.09 Thousand EUR | 380.89% |
2010 Q3 | 140.27 Thousand EUR | 0.0% |
2010 Q2 | 140.27 Thousand EUR | 0.0% |
2009 FY | 116.67 Thousand EUR | 0.0% |
2009 Q1 | 29.16 Thousand EUR | 0.0% |
2009 Q4 | 140.27 Thousand EUR | 380.9% |
2009 Q3 | 29.16 Thousand EUR | 0.0% |
2009 Q2 | 29.16 Thousand EUR | 0.0% |
2008 Q4 | 29.16 Thousand EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
ABIONYX Pharma SA | -3.51 Million EUR | 144.559% |
ABIVAX Société Anonyme | -147.74 Million EUR | 101.061% |
Adocia SA | -21.16 Million EUR | 107.407% |
Aelis Farma SA | -5.07 Million EUR | 130.87% |
Biophytis S.A. | -17.02 Million EUR | 109.207% |
Advicenne S.A. | -7.03 Million EUR | 122.295% |
IntegraGen SA | -171.39 Thousand EUR | 1014.577% |
Medesis Pharma S.A. | -3.95 Million EUR | 139.59% |
Neovacs S.A. | -8.74 Million EUR | 117.929% |
NFL Biosciences SA | -3.74 Million EUR | 141.852% |
Plant Advanced Technologies SA | 79.16 Thousand EUR | -1880.036% |
Quantum Genomics Société Anonyme | -3.17 Million EUR | 149.436% |
Sensorion SA | -22.06 Million EUR | 107.105% |
Theranexus Société Anonyme | -6.82 Million EUR | 122.958% |
TME Pharma N.V. | -6.73 Million EUR | 123.272% |
Valbiotis SA | -7.36 Million EUR | 121.275% |
TheraVet SA | -1.57 Million EUR | 199.801% |
Valerio Therapeutics Société anonyme | -20.34 Million EUR | 107.705% |
argenx SE | -272.91 Million EUR | 100.574% |
BioSenic S.A. | -28.77 Million EUR | 105.447% |
Celyad Oncology SA | -8.44 Million EUR | 118.556% |
DBV Technologies S.A. | -67.26 Million EUR | 102.33% |
Galapagos NV | 211.69 Million EUR | 99.26% |
Genfit S.A. | -28.89 Million EUR | 105.425% |
GeNeuro SA | -14.75 Million EUR | 110.623% |
Hyloris Pharmaceuticals SA | -15.38 Million EUR | 110.192% |
Innate Pharma S.A. | -7.57 Million EUR | 120.708% |
Inventiva S.A. | -110.42 Million EUR | 101.42% |
MaaT Pharma SA | -19.71 Million EUR | 107.95% |
MedinCell S.A. | -25.03 Million EUR | 106.261% |
Nanobiotix S.A. | -39.7 Million EUR | 103.949% |
Onward Medical N.V. | -36.18 Million EUR | 104.333% |
Oryzon Genomics S.A. | -3.35 Million EUR | 146.752% |
OSE Immunotherapeutics SA | -23 Million EUR | 106.815% |
Oxurion NV | -18.96 Million EUR | 108.264% |
Pharming Group N.V. | -9.75 Million EUR | 116.067% |
Poxel S.A. | -35.09 Million EUR | 104.467% |
GenSight Biologics S.A. | -26.22 Million EUR | 105.979% |
Transgene SA | -22.32 Million EUR | 107.021% |
Financière de Tubize SA | 88.15 Million EUR | 98.222% |
UCB SA | 343 Million EUR | 99.543% |
Valneva SE | -101.42 Million EUR | 101.545% |
Vivoryon Therapeutics N.V. | -28.34 Million EUR | 105.531% |